Graft-versus-host-disease (GVHD) is a major complication associated with allogeneic hematopoietic cell transplantation (allo-HCT). Antithymocyte globulin (ATG) is recommended for GVHD prophylaxis following allo-HCT, however, evidence on efficacy of ATG is conflicting. Accordingly, we undertook a systematic review. All phase III randomized controlled trials (RCTs) comparing ATG versus control for prevention of GVHD in patients undergoing allo-HCT were eligible. Medline and Cochrane databases were searched. Data on methodological quality, benefits and harms were extracted for each trial and pooled under a random effects model. Seven RCTs enrolling 733 patients met inclusion criteria. Pooled results showed no difference for overall survival with use of ATG (hazard ratio was 0.91; 95% confidence intervals (CI), 0.75 -1.10; P ¼ 0.32). There was a significant benefit for prevention of grade III/IV acute GVHD (risk ratio (RR) ¼ 0.51; 95% CI, 0.27 -0.94; P ¼ 0.03). There was no benefit associated with ATG use for prevention of either grade II (RR ¼ 0.79; 95% CI, 0.48 -1.30; P ¼ 0.35) or grade I acute GVHD (RR ¼ 1.42; 95% CI, 0.75 -2.69; P ¼ 0.28). Use of ATG was not associated with significant reduction in non-relapse mortality (RR ¼ 0.74; 95% CI, 0.53 -1.03; P ¼ 0.08). Future trials with adequate sample size are required to provide more definitive answers.
Introduction
Despite substantial progress in our understanding of the complex immunobiological aspects involved in hematopoietic cell allografting coupled with advances in HLA typing by introducing high resolution DNA sequencing for determining donor suitability, graft-versus-host-disease (GVHD) is a major clinical complication associated with allogeneic hematopoietic cell transplantation (allo-HCT) and results in significant morbidity and mortality. 1, 2 Non-relapse mortality (NRM) in patients who develop acute GVHD has been estimated to be in the range of 28 to 92%. The 3-year risk for NRM in patients with chronic GVHD ranges from 28 to 48% depending on the extent of GVHD (limited versus extensive chronic GVHD). Effective prophylaxis with immune-suppressants is key to prevention of acute GVHD. 3 Antithymocyte globulin (ATG) is one of several immunosuppressive agents currently used for GVHD prophylaxis following allo-HCT. It exerts its immunomudulatory function primarily by in vivo depletion of T-lymphocytes. 4, 5 The effect of ATG for the prevention of GVHD following allo-HCT has been evaluated in several randomized controlled trials (RCTs). However, data on the efficacy of ATG use for the prevention of GVHD has been conflicting across RCTs. Although the RCT published in 2009 by Finke et al. 6 showed that ATG has a beneficial effect in preventing GVHD, the RCT by Champlin et al. 7 appears to contradict these findings. Informed clinical decision making requires synthesis of all evidence. Therefore the objective of this manuscript is to perform a systematic review on the efficacy of ATG for GVHD prophylaxis in patients undergoing allo-HCT.
Patients and methods

Trials and patients
All completed phase III RCTs comparing use of ATG versus control for the prevention of GVHD in patients undergoing allo-HCT were eligible for inclusion.
Identification of RCTs
We used the comprehensive search strategies described by Haynes and colleagues 8 to identify all relevant RCTs in the Medline (PubMed) and Cochrane database of RCTs published through April 2010. The search terms used to identify potentially relevant RCTs are described as follows: ('Antilymphocyte Serum'(Mesh) and 'graft vs host disease'(Mesh)) and ('Clinical Trial' (Publication Type) or 'Clinical Trials as Topic'(Mesh) or 'Controlled Clinical Trial' (Publication Type) or 'Clinical Trial, Phase IV' (Publication Type) or 'Clinical Trial, Phase III' (Publication Type) or 'Meta-Analysis as Topic'(Mesh)). All references of relevant articles were further scanned to identify studies that might be eligible for inclusion. We also performed a manual search of abstracts from the annual proceedings of the American Society of Hematology (2008 Hematology ( -2009 
Outcomes
Data were extracted on benefits and harms associated with treatment (that is, ATG versus no ATG). The outcomes include: (1) GVHD incidence, severity and relapse, (2) overall survival (OS) and (3) NRM.
Data extraction
Two reviewers (AM, AK) independently screened the titles and abstracts of all studies identified through literature search to assess whether they met the predefined inclusion criteria. Same set of reviewer's extracted data on benefits (incidence of GVHD, severity and relapse, OS) and harms (NRM) associated with compared treatments using a standardized data extraction form.
Assessment of methodological quality
We also extracted data on the methodological domains relevant to minimizing bias and random error in the conduct and analysis of the trials. 9, 10 Data were extracted for the following methodological quality domains: generation of allocation sequence, allocation concealment, blinding (if applicable), a priori sample size calculation, power analysis, description of dropouts and withdrawals, data analysis according to intent-to treat principle and funding source. Any discrepancies in data extraction were resolved by consensus amongst authors.
Data analysis and statistical methods
Time-to-event (OS), and dichotomous data (incidence of GVHD, relapse and NRM) were pooled and are reported as hazard ratio and risk ratio (RR), 11 respectively, with 95% confidence intervals (CI) under a random effects model.
12
If time-to-event data were unavailable for direct extraction, we extracted data according to the method described by Tierney et al. 13 This method allows calculation of the hazard-ratio from different parameters using indirect calculation of the variance and the number of observed minus expected events. A formal statistical test for heterogeneity using the chi square 12 and
14) test was performed. The possibility of publication bias was also assessed using the Begg and Egger funnel plot method. 15, 16 The meta-analysis was performed using Review Manager Software (Review Manager, Version 5.1. The Cochrane Collaboration (2011), Copenhagen). The work is reported according to the PRISMA guidelines. 17 
Results
Identification of studies
The process of identification and selection of studies is illustrated in Figure 1 . The initial search of PubMed and Cochrane database of RCTs yielded 141 citations of which 7 RCTs met the inclusion criteria. 6,7,18 -21 These seven RCTs enrolled a total of 733 patients. Table 1 summarizes details related to patient characteristics in the included trials.
Methodological quality of RCTs
The methodological quality of the included studies is shown in Table 2 . The method of generation of randomization sequence was adequately described in 29% (2/7) of RCTs. The treatment allocation was adequately concealed in 57% (4/7) of RCTs. All the included RCTs adequately described withdrawals and drop-outs. All RCTs except the RCT published by Weiden et al. 21 analyzed data according to intent-to treat principle. A priori calculation of sample size, a and b error and expected difference for primary outcome was reported in 57% (4/7) of RCTs.
Publication bias
The assessment for publication bias using the Begg and Egger funnel plot for the outcome of OS (P ¼ 0.198) showed a symmetric distribution indicating low likelihood of publication bias (figure not shown). However, with only seven eligible studies, there is low power to detect publication bias.
Initial search of Pubmed and meeting abstracts N=141
Included for further evaluation N=12 
OS
Data on survival was extractable from all trials enrolling total of 733 patients. The pooled results showed a statistically nonsignificant benefit for OS with use of ATG for the prevention of GVHD ( Figure 2 ). The pooled hazard ratio for the comparison of ATG versus no ATG was 0.91 (95% CI, 0.75 -1.10; P ¼ 0.32). There was no heterogeneity among included studies (I 2 ¼ 0%).
Incidence of acute GVHD
As shown in Figure 3 , there was a statistically significant benefit associated with ATG use for the prevention of severe grade III/IV acute GVHD (five RCTs, 609 patients). The RR was 0.51 (95% CI, 0.27 -0.94; P ¼ 0.03). There was a statistically significant heterogeneity among included trials (I 2 ¼ 53%). There was a statistically nonsignificant benefit with use of ATG for the prevention of either grade II (three RCTs, 238 patients; RR ¼ 0.79; 95% CI, 0.48 -1.30; P ¼ 0.35, I
2 ¼ 0%) or grade I acute GVHD (two RCTs, 185 patients; RR ¼ 1.42; 95% CI, 0.75 -2.69; P ¼ 0.28, I
2 ¼ 0%).
NRM
NRM data were extractable from 29% (2/7) of RCTs enrolling a total of 371 patients. As illustrated in Figure 4a , use of ATG was not associated with any significant effect on NRM. The RR was (9) 2 (5) Abbreviations: ATG, antithymocite globulin; NR, not reported. 
Relapse
Data on relapse were extractable from 29% (2/7) of RCTs enrolling a total of 268 patients. Use of ATG was not associated with any significant effect on increasing incidence of relapse (Figure 4b ). The resulting RR was 1.19 (95% CI, 0.77 -1.84; P ¼ 0.44). An I 2 of 0% indicated an absence of heterogeneity among included studies.
Sensitivity analyses
As shown in Figure 2 , sensitivity analysis according to type of ATG (rabbit versus horse) did not show any statistically significant benefit for OS. The pooled HR for OS was 0.94 (95% CI, 0.75 -1.17) versus 0.82 (95% CI, 0.56 -1.21) in RCTs using rabbit versus horse ATG, respectively. Test of interaction between subgroups showed a statistically nonsignificant difference (P ¼ 0.56). Additional sensitivity analyses according to methodological quality domains and source of funding (public versus private) did not change the results in any way.
Discussion
Acute GVHD remains a serious clinical complication for patients undergoing allo-HCT for various hematologic and non-hematologic diseases. Advances in our understanding of the pathogenesis of GVHD have shown that immunologic events leading to the development of clinical acute GVHD occur soon after infusion of the allograft containing mature donor T cells. 22 As a result, it appears logical that a pre-emptive strategy should be considered before the clinical diagnosis of acute GVHD is established. This becomes more important when considering the increasing number of allo-HCT being performed nowadays, worldwide, using unrelated or mismatched donors, which are inherently associated with higher incidence of acute GVHD and consequently chronic GVHD. 23, 24 Similarly, introduction of less ablative preparative regimens has facilitated performing allo-HCT in patients of more advanced ages who are also known to be at higher risk of developing acute and chronic GVHD. 25 Incorporation of ATG as an in vivo T-cell depleting strategy to reduce the risk of acute GVHD is being more commonly used nowadays; but it is not yet a uniform practice in transplant centers throughout the world. This is likely due to several factors including the increased risk of developing serious infections, such as EBV, as a result of prolonged T-cell immune suppression; and increased risk of disease relapse form dampening the bona fide graft-versus malignancy effect due to depletion of donor effector T cells. 3 Several studies suggest that T-cell recovery is delayed following ATG administration; consequently, posing an increased risk of infections as well as disease relapse. ATG has also been shown to modify newly formed T cells in the early recovery period. 4 This systematic review and meta-analysis represents, to our knowledge, the first extensive assessment evaluating the effect of ATG use in preventing acute GVHD in patients undergoing allo-HCT. Three different sources of ATG were used in the various studies analyzed herein: Figure 2 Forest plot of overall survival. The summary effect estimate (hazard ratio) for individual RCTs are indicated by black rectangles (the size of the rectangle is proportional to the study weight), with the lines representing 95% CIs. The overall summary effect estimate (hazard ratio) and 95% CI are indicated by the diamond below.
Antithymocyte globulin for acute GVHD prophylaxis A Kumar et al types of rabbit ATG, namely Thymoglobulin (Genzyme Corporation, Cambridge, MA, USA) and ATG-Fresenius (ATG-F; Fresenius Biothech, Graefelfing, Germany). The current results of this meta-analysis suggest a protective effect of ATG in reducing the incidence of grade III/IV acute GVHD. Administration of ATG, however, did not reduce the incidence of grade I or II acute GVHD and did not ultimately impact OS. It is important to note that studies analyzed in this systematic review differ in regards to cell source (bone marrow versus mobilized peripheral blood stem cells), ablative intensity of conditioning regimens (reduced intensity versus myeloablative), donor source (matched-related versus unrelated donors versus mismatched donors) and primary diseases for which allo-HCT was intended. Some studies have defined criteria for inclusion of a vast array of malignant hematologic disorders whereas others do not specify reason for allo-HCT. The beneficial findings described above did not appear to be impacted by a particular source of ATG or methodological quality of RCTs.
The impact of ATG on chronic GVHD was not assessed in any of the included studies, however, observational data suggested a preference for treatment with ATG. 26 As completion of the review, one included study reported results of long term follow-up including incidence of chronic GVHD. 27 Although the results of the long-term follow-up were not included in our analysis, they are in line with prior study findings. Additionally, a preference for treatment with ATG in reducing incidence of chronic GVHD was observed which remains to be validated in additional studies.
In summary, the results from this systematic review show that whereas ATG is effective in preventing grade III/IV acute GVHD, it does not impact OS. This is in contrast to the report of a recent large observational study which found ATG to be associated with reduced likelihood of grade II-IV acute GVHD at the expense of DFS and OS in a cohort of 1676 patients. 28 The trials identified by this review in general are small in sample size. Trial sequential analysis 29 733 patients in this meta-analysis, there is only 15% power to detect a relative risk reduction of 9% observed in this study at a 0.05 level of significance. Furthermore, in order to have 80% power to detect a moderate relative risk reduction of 20% at a 0.05 level of significance, 1413 patients would be needed. Accordingly, the findings of this review emphasize on the need for a large and well-conducted RCT to definitively answer the question related to the effect of ATG for the prevention of GVHD.
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Test for overall effect: Z = 1.76 (P = 0.08) Figure 4 Forest plot of NRM (a), and relapse (b). The summary effect estimate (hazard ratio) for individual RCTs are indicated by black rectangles (the size of the rectangle is proportional to the study weight), with the lines representing 95% CIs. The overall summary effect estimate (hazard ratio) and 95% CI are indicated by the diamond below.
Antithymocyte globulin for acute GVHD prophylaxis A Kumar et al
